ZELBORAF® (vemurafenib) as monotherapy in the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma

Evaluation des Technologies de Santé

Requester : Department of Pharmacy and Medicines, Ministry of Health (DPM) Ministry of Health) on behalf of the following Ad-hoc committee: DPM, the Compulsory Insurance Scheme (CNAM), the Technical Committee for Pharmaceutical Products

Objective : To support pricing negotiations and potential coverage decisions

This HTA report examines the clinical and economic implications of this technology and outlines the criteria considered by INEAS (burden of the disease, unmet needs, net benefit, comparative risks, cost effectiveness and budget impact) which led to the final HTA recommendations.

We invite you to read the full assessment by visiting our website at the following link: [https://portail.ineas.tn].

Recommandations : On the basis of the criteria considered, INEAS recommends the coverage of Zelboraf® as a first-line treatment for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, subject to a price reduction.

This document is a translation of the original HTA report written in French and validated by the College of Experts of INEAS. The original report is available on the website: https://portail.ineas.tn/

< Retour